Mr. Chris Bunka reports

VIPOVA(TM) BY LEXARIA ANNOUNCES NEW PRESIDENT

As part of its broader business transition into the alternative health industry, Lexaria Corp. has hired Tom Ihrke as president of its U.S. subsidiary to oversee the rollout and sale of its ViPova brand of CBD-infused (cannabidiol) teas. Lexaria has also named Mr. Ihrke as executive vice-president of U.S. operations of Lexaria.

Mr. Ihrke has been working with Lexaria as a part-time consultant over the last eight years. Mr. Ihrke's extensive experience investing in and advising small companies will prove extremely valuable to Lexaria as it enters the exciting and fast-growing alternative health industry. In addition to advising Lexaria with its business strategy and capital market activities, Mr. Ihrke will oversee all aspects of the ViPova brand, including the day-to-day business, operations, as well as sales and marketing. The company's goal is to develop internationally recognized lines of healthy food and beverage products, initially focusing on tea and coffee.

"I'm very pleased to welcome Tom to our executive management team. He is a highly skilled and effective manager who is clearly able to take ViPova to another level and help us as we expand our brands and offerings in the CBD sector," said Chris Bunka, chief executive officer of Lexaria.

ViPova uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova-branded tea. ViPova uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova has this groundbreaking technology for CBD/lipid infusion.

As well, Lexaria announces it has granted a total of 1,425,000 stock options to a number of executives, directors and consulting employees, all priced at 11 U.S. cents. The company makes note that 850,000 existing options are due to expire on Jan. 20, 2015, unless exercised before then.

All issued shares will be subject to a hold period, for any resale into the United States under Rule 144, of six months and one day. The share issuance is subject to normal regulatory approvals.

We seek Safe Harbor.